Filing Details

Accession Number:
0001209191-23-046243
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-17 16:10:57
Reporting Period:
2023-08-15
Accepted Time:
2023-08-17 16:10:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1719395 Eargo Inc. EAR Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 273879804
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1827198 Adam Laponis C/O Eargo, Inc.
2665 North First Street, Suite 300
San Jose CA 95134
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-08-17 19 $3.24 3,152 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2023-08-15 97,500 $0.00 97,500 $3.31
Common Stock Stock Option (Right to Buy) Acquisiton 2023-08-15 82,500 $0.00 82,500 $3.31
Common Stock Stock Option (Right to Buy) Disposition 2023-08-15 82,500 $0.00 82,500 $11.58
Common Stock Stock Option (Right to Buy) Acquisiton 2023-08-15 82,500 $0.00 82,500 $3.31
Common Stock Stock Option (Right to Buy) Disposition 2023-08-15 82,500 $0.00 82,500 $11.58
Common Stock Stock Option (Right to Buy) Acquisiton 2023-08-15 824 $0.00 824 $3.31
Common Stock Stock Option (Right to Buy) Disposition 2023-08-15 824 $0.00 824 $1,051.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
97,500 2033-08-14 No 4 A Direct
82,500 2033-01-31 No 4 A Direct
0 2033-01-31 No 4 D Direct
82,500 2033-01-31 No 4 A Direct
0 2033-01-31 No 4 D Direct
824 2031-01-28 No 4 A Direct
0 2031-01-28 No 4 D Direct
Footnotes
  1. Reflects the number of shares of Common Stock that were sold to satisfy tax withholding requirements on vesting of restricted stock units pursuant to the Issuer's automatic sell to cover program, and does not represent a discretionary sale by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $3.23 to $3.24, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the shares of Common Stock sold at each separate price within the range set forth in this footnote.
  3. The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
  4. The Issuer cancelled the Stock Option in exchange for a new option having a lower exercise price.
  5. The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
  6. The Stock Option vests and becomes exercisable in 8 equal quarterly installments, with the first installment vesting on November 15, 2023, provided, that, any unvested portion of the Stock Option shall vest and become exercisable upon attainment of a 360-day VWAP (volume weighted average price) of $20.00 for the Issuer's Common Stock, in either case, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
  7. The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date.
  8. The Stock Option shall vest and become exercisable with respect to 16 quarterly installments commencing on February 15, 2021, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date.
  9. On January 17, 2023, the Issuer effected a 1-for-20 reverse stock split of its Common Stock (the "Reverse Stock Split"). These securities reflect the Reverse Stock Split.